Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study-Reference-Cited by-同舟云学术

Effects of glucagon‐like peptide‐1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study

Published:2021-06-16 Issue:12 Volume:12 Page:2162-2171
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J of Diabetes Invest

Author:

Kuwata Hitoshi¹²,Yabe Daisuke¹³⁴^ORCID,Murotani Kenta⁵^ORCID,Fujiwara Yuuka¹,Haraguchi Takuya¹²³,Kubota Sodai¹³^ORCID,Kubota‐Okamoto Saki¹³,Usui Ryota¹²^ORCID,Ishitobi Minori²,Yamazaki Yuji¹²,Hamamoto Yoshiyuki¹²^ORCID,Kurose Takeshi¹⁶^ORCID,Seino Yusuke⁷^ORCID,Yamada Yuichiro¹²,Seino Yutaka¹²^ORCID

Affiliation:

1. Yutaka Seino Distinguished Center for Diabetes Research Kansai Electric Power Medical Research Institute Kobe Japan

2. Center for Diabetes, Endocrinology and Metabolism Kansai Electric Power Hospital Osaka Japan

3. Department of Diabetes, Endocrinology and Metabolism Gifu University Graduate School of Medicine Gifu Japan

4. Division of Molecular and Metabolic Medicine Kobe University Graduate School of Medicine Kobe Japan

5. Biostatistics Center Graduate School of Medicine, Kurume University Kurume Japan

6. Nakanoshima Clinic Osaka Japan

7. Department of Endocrinology and Metabolism Fujita Health University Toyoake Japan

Funder

Japan Association for Diabetes Education and Care

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13598

Reference40 articles.

1. The journey to understanding incretin systems: Theory, practice and more theory

2. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

3. Incretin therapy for diabetes mellitus type 2

4. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

5. GIP and GLP-1, the two incretin hormones: Similarities and differences

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations of delayed gastric emptying with peri‐operative use of glucagon‐like peptide‐1 receptor agonists;Medical Journal of Australia;2023-11-27

2. Incretin hormones and type 2 diabetes;Diabetologia;2023-07-11

3. Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes;Diabetology International;2023-04-10

4. Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy;Journal of Diabetes Investigation;2023-03-15

5. Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy);Diabetes, Obesity and Metabolism;2022-11-02